ALM Almirall, S.A.

11.17USD10.18 EUR · BME-1.36%Mkt Cap: 2.43B USDP/E: 29.94

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, a…

Institutional holders10 on file

Key Statistics

Company
Market Cap2.43B USD
Enterprise Value2.32B USD
Revenue (TTM)1.30B USD
Gross Profit955.99M USD
Net Income (TTM)50.62M USD
Revenue/Share5.96 USD
Last Price11.17 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.1K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0157097017
Valuation
P/E (Trailing)29.94
P/E (Forward)19.46
PEG1.00
EV/EBITDA8.61
EV/Revenue1.79
P/S1.88
P/B1.44
EPS (TTM)0.37 USD
EPS (Forward)0.58 USD
52W Range
10.769% of range15.33
52W High15.33 USD
52W Low10.76 USD
Profitability
Gross Margin78.66%
Oper. Margin9.60%
EBITDA Margin20.75%
Profit Margin4.17%
ROE3.10%
ROA1.97%
ROIC2.78%
ROCE3.36%
Growth
Revenue Growth9.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF191.35M USD
CapEx (TTM)150.60M USD
FCF Margin7.20%
FCF Yield3.84%
Net Debt-124.71M USD
Net Debt/EBITDA-0.46
Net Debt/FCF-1.34
Balance Sheet
Debt/Equity0.23
Current Ratio2.51
Quick Ratio1.80
Book Value/Sh7.78 USD
Cash/Share2.01 USD
Dividends
Fwd Div Rate0.21 USD
Trail. Div Rate0.00 USD
Div. Yield1.81%
5Y Avg Yield1.84%
Payout Ratio66.79%
Ex-Div DateMay 14, 2026
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.69 USD
Upside (mean)+40.6%
Target Range12.28 USD – 19.19 USD
12.28+40.6% to mean19.19
# Analysts12
Ownership
Shares Out.217.61M
Float78.27M
Insiders64.96%
Institutions15.90%
Technical
SMA 5011.44 (-2.4%)
SMA 20012.42 (-10.1%)
Beta0.08
S&P 52W Chg12.00%
Avg Vol (30d)107.34K
Avg Vol (10d)206.72K
Technical Indicators
RSI (14)39.8
MACD0.0092
MACD Signal0.0828
MACD Hist.-0.0736
BB Upper12.30 USD
BB Middle11.67 USD
BB Lower11.04 USD
BB Width10.84%
ATR (14)0.3160 USD
Vol Ratio (20d)0.75x

About Almirall (BME: ALM)

›

Almirall (BME: ALM) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,108 employees.

The shares were at 10.18 EUR on 19 November 2026, down 18.7% over 52 weeks. Its 52-week range is 9.810 EUR to 13.98 EUR: the price is 27.2% below the high and 3.8% above the low.

At a market capitalisation of 2.22B EUR, it trades at 29.9 times trailing earnings and 19.5 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 21% for ALM. It pays a dividend yielding 1.81% (it pays out 67% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Almirall reports return on equity of 3.1%, an operating margin of 9.6% and revenue up 9.8% year over year.

It holds more cash than debt, a net cash position of 113.70M EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 14.31 EUR is 40.6% above the current price. The next earnings report is expected on 22 February 2027.